Table 3. Univariate and multivariate prognostic analysis of DFS for chemotherapy and trastuzumab-naive DCIS-Mi patients.
| Characteristics | Univariate | Multivariate | ||
|---|---|---|---|---|
| Mean survival(months) | P value | HR(95%CI) | P value | |
| Age(yrs) | 0.006* | 0.021* | ||
| < 50 | 45.7 | 21.1(1.6-281.6) | ||
| ≥50 | 70.3 | |||
| Invasive foci | 0.011* | 0.754 | ||
| 1 | 67.4 | 1.52(0.11-20.80) | ||
| ≥2 | 33.0 | |||
| ER status | 0.439 | 0.887 | ||
| Positive | 66.5 | 0.84(0.08-9.10) | ||
| Negative | 47.5 | |||
| PR status | 0.433 | 0.123 | ||
| Positive | 67.0 | 0.16(0.02-1.65) | ||
| Negative | 47.7 | |||
| HER2 status | 0.006* | 0.019* | ||
| Positive | 42.6 | 21.8(1.7-286.8) | ||
| Negative | 70.0 | |||
Abbreviation: DFS=disease free survival. DCIS-Mi=Ductal carcinoma in situ with microinvasion. HR=hazard ratio. ER=estrogen receptor. PR=progesterone receptor. HER2=human epidermal growth factor receptor 2.
*
statistically significant.